Trial Profile
A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Mar 2023
Price :
$35
*
At a glance
- Drugs NT 501 (Primary)
- Indications Retinal telangiectasis
- Focus Registrational; Therapeutic Use
- Sponsors Neurotech USA
- 03 Feb 2023 Status changed from active, no longer recruiting to completed.
- 02 Nov 2022 Results presented in a Neurotech Pharmaceuticals media release.
- 21 Sep 2020 Planned End Date changed from 31 Mar 2022 to 31 Aug 2022.